Kuntai Capsules Improve Premature Ovarian Failure by Regulating AMPK-Mediated Autophagy
- PMID: 40789984
- DOI: 10.1007/s43032-025-01949-w
Kuntai Capsules Improve Premature Ovarian Failure by Regulating AMPK-Mediated Autophagy
Abstract
Background: Premature ovarian failure (POF) is a gynecological endocrine disorder with current treatments having limitations. Kuntai capsule (KTC), a traditional Chinese medicine formulation, is thought to be beneficial for POF, but its mechanism is unclear. Network pharmacology can help explore drug mechanisms.
Methods: A POF rat model was established using cyclophosphamide (CTX). Rats received low-dose KTC (0.6 g/kg/d), high-dose KTC (1.8 g/kg/d), or dehydroepiandrosterone (DHEA, positive control). Ovarian function was evaluated via histopathology, hormone assays (ELISA), apoptosis (TUNEL/flow cytometry), autophagy markers (Western blot), and network pharmacology.
Results: KTC treatment (especially high-dose) ameliorated POF in CTX-treated rats, as shown by increased ovarian weight, restored estrus cycle, and improved follicle development. The serum estradiol (E2), anti-mullerian hormone (AMH), and superoxide dismutase (SOD) levels increased, whereas the follicle-stimulating hormone (FSH), malondialdehyde (MDA), and reactive oxygen species (ROS) levels decreased following KTC treatment. KTC also alleviated ovarian cell apoptosis and autophagy, with higher-dose KTC being more effective. Network pharmacology predicted AMPK/mTOR pathway involvement. Western blot confirmed KTC activated the AMPK/mTOR signaling, downregulated autophagy markers (LC3B-II/I, Beclin1), and upregulated P62. Autophagy inhibition (via 3-MA) mirrored KTC effects, while mTOR blockade (rapamycin) reversed them.
Conclusions: KTC ameliorates POF by inhibiting excessive ovarian autophagy through AMPK/mTOR pathway activation, providing a mechanistic basis for its clinical use.
Keywords: AMPK/mTOR signaling pathway; Autophagy; Follicular granulosa cell; Kuntai capsule; Premature ovarian failure.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics Approval and Consent to Participate: All animal procedures were approved by the Animal Ethical and Welfare Committee of Guangzhou Miles Biosciences Co. Ltd (No. IACUC-MIS20230069; title: Kuntai capsule improves premature ovarian failure; date of approval: Sept 2, 2024). The manuscript was reported in accordance with the ARRIVE guidelines for the reporting of animal experiments. Consent for Publication: Not applicable. Competing Interests: The authors declare that they have no competing interests.
Similar articles
-
Exosomes from adipose-derived stem cells alleviate premature ovarian failure via blockage of autophagy and AMPK/mTOR pathway.PeerJ. 2023 Dec 14;11:e16517. doi: 10.7717/peerj.16517. eCollection 2023. PeerJ. 2023. PMID: 38107591 Free PMC article.
-
Mechanisms of cell senescence and apoptosis in cyclophosphamide-induced premature ovarian failure in rats.J Ovarian Res. 2025 Jul 31;18(1):172. doi: 10.1186/s13048-025-01759-3. J Ovarian Res. 2025. PMID: 40745333 Free PMC article.
-
Kuntai capsule attenuates premature ovarian failure through the PI3K/AKT/mTOR pathway.J Ethnopharmacol. 2019 Jul 15;239:111885. doi: 10.1016/j.jep.2019.111885. Epub 2019 Apr 19. J Ethnopharmacol. 2019. Retraction in: J Ethnopharmacol. 2022 May 10;289:115091. doi: 10.1016/j.jep.2022.115091. PMID: 31009706 Retracted.
-
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2024 Jan 4;1:CD012693. doi: 10.1002/14651858.CD012693.pub3. PMID: 29388198 Free PMC article. Updated.
-
The physiology and clinical utility of anti-Mullerian hormone in women.Hum Reprod Update. 2014 May-Jun;20(3):370-85. doi: 10.1093/humupd/dmt062. Epub 2014 Jan 14. Hum Reprod Update. 2014. PMID: 24430863
References
-
- Chon SJ, Umair Z, Yoon MS. Premature ovarian insufficiency: past, present, and future. Front Cell Dev Biol. 2021;9: 672890. https://doi.org/10.3389/fcell.2021.672890 . - DOI - PubMed - PMC
-
- Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. Best Pract Res Clin Endocrinol Metab. 2024;38(1): 101823. https://doi.org/10.1016/j.beem.2023.101823 . - DOI - PubMed
-
- Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol Oncol Res. 2020;26(1):63–78. https://doi.org/10.1007/s12253-018-00569-x . - DOI - PubMed
-
- Umer A, Khan N, Greene DL, Habiba UE, Shamim S, Khayam AU. The therapeutic potential of human umbilical cord derived mesenchymal stem cells for the treatment of premature ovarian failure. Stem Cell Rev Rep. 2023;19(3):651–66. https://doi.org/10.1007/s12015-022-10493-y . - DOI - PubMed
-
- Cai L, Zong DK, Tong GQ, Li L. Apoptotic mechanism of premature ovarian failure and rescue effect of traditional Chinese medicine: a review. Journal of Traditional Chinese Medicine = Chung i tsa chih ying wen pan. 2021;41(3):492–8. https://doi.org/10.19852/j.cnki.jtcm.2021.03.017 .
LinkOut - more resources
Full Text Sources
Miscellaneous